Table 2.
Summary of evidence of bland transarterial embolization (TAE)
Authors | n | Summary |
---|---|---|
Kluger, et al. [23] (2014) | 25 | TACE vs TAE prior to transplantation |
TAE patients were less likely than TACE patients to require 2 procedures (P=0.04) | ||
Explant tumors were completely necrotic for 36% of TAE patients, 26% of TACE patients | ||
3 year survival was higher for TAE (78%) than TACE (74%), (P=0.66) | ||
3 year recurrence free survival rates was TAE (72%) and TACE (68%), P=0.83 | ||
Massarweh, et al. [24] (2016) | 405 | TAE vs TACE |
No significant difference in mean survival (20.1 vs 23.1 months, P=0.84) | ||
No significant difference in risk of death associated with TAE. | ||
Brown, et al. [25] (2016) | 101 | Embolization with microspheres alone vs Doxorubicin-Eluting Microspheres |
Similar adverse events in both groups (38% vs 40%, P=0.48) | ||
No significant difference in RECIST response, median progression free survival and overall survival. |